David Mauro
Chief Tech/Sci/R&D Officer at RECURSION PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 31/03/2024
Profile
Presently, David J. Mauro holds the position of Chief Medical Officer for Prelude Therapeutics, Inc. Dr. Mauro previously occupied the position of Chief Medical Officer & Executive Vice President at Advaxis, Inc. and Chief Medical Officer for Checkmate Pharmaceuticals, Inc. Dr. Mauro received an undergraduate degree from Cornell University and a doctorate from Temple University School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
09/02/2024 | 244,629 ( 0.12% ) | 2 M $ | 31/03/2024 |
David Mauro active positions
Companies | Position | Start |
---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2023 |
Former positions of David Mauro
Companies | Position | End |
---|---|---|
CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | 07/04/2023 |
CHECKMATE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15/10/2019 |
AYALA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2016 |
MERCK & CO., INC. | Director/Board Member | 01/01/2014 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Training of David Mauro
Cornell University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
RECURSION PHARMACEUTICALS, INC. | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
Private companies | 3 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- David Mauro